Jamaican Property and Tier-3 License assets will set up strong tourism and export markets
Weekend Unlimited Inc. (OTC: WKULF) (CSE: POT)having announced a Letter of Intent on 1 November 2018 to acquire R&D Pharma’s Jamaican interests, has now entered into a definitive agreement with R&D Pharma, which is anticipated to close next week.
R&D Pharma (“RDP”) is a Canadian company building a vertically integrated medical cannabis business in Jamaica. RDP has secured a Tier-3 Cultivator’s License, which allows for full cultivation of cannabis plants on land of over 5 acres, which in this case applies to the 98-acre RDP property.
R&D Pharma Highlights include:
- Approved Tier-3 cultivators license
- Medical tourism in Jamaica, plus phenotyping with Jamaican sativas, to brand and export internationally recognized strains, extracts, and infused products
- Will be a significant exporter of branded full spectrum extracts as well as extracted cannabinoids from one of world‘s lowest cost geographies for growing cannabis
“Upon signing this deal, we are excited to accelerate operations in Jamaica. There has been tremendous work accomplished on the property by the team on the ground and the cultivation results have been impressive in both quality and economically,” noted Mr. Paul Chu, Weekend Unlimited President and CEO.
Weekend Unlimited is capitalizing on its vast industry relationships to establish a lifestyle brand featuring premium products and delivering life’s highest moments. The company aggregates and scales small to medium brands, primarily in the categories of flower, extracts and edibles. Weekend Unlimited brands have best of class operations, distribution and strong revenue trajectories, making them ideal candidates for the deployment of capital and expertise through access to technologies, infrastructure and centralized systems.